Xeptiva develops first-in-class therapeutic vaccines targeting chronic inflammation in companion animals, specifically addressing conditions such as canine atopic dermatitis and feline atopic skin syndrome. By enhancing the healthspan and lifespan of pets, Xeptiva aims to provide effective, affordable immunotherapies that improve the quality of life for animals suffering from these chronic conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic inflammatory conditions like canine atopic dermatitis and feline atopic skin syndrome significantly reduce the quality of life for companion animals. Current treatments often provide only symptomatic relief and may have undesirable side effects, leaving a need for more effective and affordable therapies.
Solution
Xeptiva is developing therapeutic vaccines designed to actively immunize companion animals against chronic inflammation. Their approach aims to improve both the healthspan (quality of life) and lifespan (years of life) of pets suffering from conditions like atopic dermatitis and feline atopic skin syndrome. By targeting the underlying causes of chronic inflammation, Xeptiva seeks to provide a more effective and potentially disease-modifying treatment option compared to traditional symptomatic therapies. The vaccines are designed to be simple, affordable, and highly effective, offering a disruptive approach to managing these challenging conditions in companion animals.
Target Audience
The primary target audience includes veterinarians and pet owners seeking more effective and affordable treatments for chronic inflammatory conditions in companion animals, specifically dogs and cats.
Features
- First-in-class therapeutic vaccines targeting chronic inflammation in companion animals.
- Focus on active immunization to provide long-lasting relief.
- Designed to improve both healthspan and lifespan of affected animals.
- Addresses conditions such as canine atopic dermatitis and feline atopic skin syndrome.